HURA

Tuhura Biosciences, Inc. (HURA) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Tuhura Biosciences, Inc. is a clinical-stage immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapies. The company operates in a single segment and has no product revenue. Key product candidates include IFx-2.0 (Phase 3 trial initiated in June 2025 for Merkel cell carcinoma) and TBS-2025 (acquired via the Kineta Merger in June 2025, planned Phase 1b/2 trial for AML).

Key Financial Metrics

Debt and Liquidity: The company entered a $50 million revolving credit facility with Parkview Holdings One LLC in April 2026. As of June 30, 2026, $3.6 million had been drawn. The facility bears 12% interest and includes a $5 million commitment fee payable in shares. Cash burn from operations was $13.0 million for the six-month period.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $1.1 million for the three months ended June 30, 2026, compared to the prior year period. This decrease is primarily due to the absence of $3.1 million in acquisition-related costs incurred in Q2 2025 for the Kineta Merger.
• Research & Development (R&D): R&D expenses increased by $1.7 million (Q2) and $2.3 million (YTD) compared to the prior year. This increase is driven by the initiation of clinical development for TBS-2025 and increased personnel/facility costs, partially offset by reduced preclinical research on discontinued programs.
• Interest Expense: Interest expense of $0.47 million (Q2) and $0.50 million (YTD) was recorded in 2026, compared to zero in the prior year, resulting from the new Parkview Credit Facility.
• Grant Income: Grant income of $0.32 million (Q2) and $0.58 million (YTD) recorded in 2025 was absent in 2026.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing capital resources, including the Parkview Credit Facility and ATM Program, to fund operations into the end of 2028. However, the company has an accumulated deficit of $157.9 million and expects to continue incurring losses.
• Financing Activities: The company raised approximately $7.8 million in gross proceeds from common stock issuances (RDO and ATM) and $3.6 million from the credit facility during the six months ended June 30, 2026.
• Key Risks:
  • Capital Requirements: Significant additional funding is required for clinical trials and commercialization. Failure to raise capital could force delays or termination of programs.
  • Regulatory Uncertainty: No products are approved; success depends on regulatory approvals which are unpredictable.
  • Debt Covenants: The Parkview facility is secured by substantially all assets and requires repayment of 75% of net profits if achieved for two consecutive quarters.
• Subsequent Events: Between June 30, 2026, and August 14, 2026, the company borrowed an additional $2.15 million under the Parkview facility and raised approximately $0.46 million via the ATM Program.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.0 million cash balance plus the remaining $46.4 million availability under the Parkview facility to fund operations through 2028 given the $13 million semi-annual operating cash burn.
• Debt Terms: Review the specific covenants and repayment triggers of the Parkview Credit Facility, particularly the 12% interest rate and the requirement to repay 75% of net profits.
• Dilution: Assess the impact of the $5 million commitment fee payable in shares (1.88 million shares) and the existing warrant overhang (approx. 32.3 million warrants outstanding).
• Clinical Milestones: Monitor the progress and topline results of the IFx-2.0 Phase 3 trial (expected H2 2027) and the initiation of the TBS-2025 Phase 1b/2 trial.
• Intangible Assets: Evaluate the $11.3 million In-Process Research and Development (IPR&D) asset and $10.7 million Goodwill recorded from the Kineta acquisition for potential impairment risks.